{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5"},{"groupId":"OG001","value":"89.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"description":"Percentage of participants with overall response was defined as the portion of participants who achieved CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. Criteria for PR: greater than or equal to (\\>=) 50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions.","groups":[{"description":"Participants received 4 capsules of ibrutinib-matching Placebo administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a complete response (CR) or partial response (PR) continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment A up to 100.1 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment A discontinued placebo treatment.","id":"OG000","title":"Placebo + Bendamustine and Rituximab (BR) (Treatment A)"},{"description":"Participants received ibrutinib capsules 560 mg (4\\*140 mg capsule) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 mg/m\\^2 IV infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a CR or PR continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment B up to 117.2 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment B continued treatment with ibrutinib at the discretion of the investigator.","id":"OG001","title":"Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)"}],"paramType":"NUMBER","populationDescription":"ITT analysis set included all randomized participants and classified according to the assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 97 months","title":"Percentage of Participants With Overall Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}